Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Hemogenyx Pharmaceuticals logo
GBX 189 -4.75 (-2.45%)
As of 12:17 PM Eastern

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Key Stats

Today's Range
189
195
50-Day Range
169.16
374
52-Week Range
160
1,200
Volume
2,507 shs
Average Volume
30,100 shs
Market Capitalization
£6.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Remove Ads
Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HEMO Stock News Headlines

“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Hemogenyx Pharmaceuticals Announces Key Corporate Changes
See More Headlines

HEMO Stock Analysis - Frequently Asked Questions

Hemogenyx Pharmaceuticals' stock was trading at GBX 402 at the beginning of the year. Since then, HEMO shares have decreased by 53.0% and is now trading at GBX 189.
View the best growth stocks for 2025 here
.

Hemogenyx Pharmaceuticals Plc (LON:HEMO) released its earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter.

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
9/30/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:HEMO
Previous Symbol
LON:SILF
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-6,890.55
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 92.42 per share
Price / Cash Flow
2.05
Book Value
GBX 0.25 per share
Price / Book
767.17

Miscellaneous

Free Float
N/A
Market Cap
£6.74 million
Optionable
Not Optionable
Beta
3.14
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (LON:HEMO) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners